Clinical and biomarker analyses of first-line nivolumab and relatlimab (nivo-rela) in advanced or resectable melanoma (mel).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lilit Karapetyan, Kimberly Ward, Shaliz Aflatooni, Denise Kalos, Carlos Moran-Segura, Bethany Withycombe, Pei-Ling Chen, Kenneth Yee Tsai, Jane Messina, Matthew Perez, Amod Sarnaik, Jonathan S. Zager, Rogerio Izar Neves, Vernon K. Sondak, Keiran Smalley, Joseph Markowitz, Andrew Scott Brohl, Zeynep Eroglu, Ahmad A. Tarhini, Nikhil I. Khushalani
Institutions: Moffitt Cancer Center, University of South Florida
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410816010